Increased Capabilities in the United States
Tjoapack is finishing up the installation of two state-of-the-art packaging lines at its Clinton, Tennessee plant to increase high-throughput sterile injectable packaging capabilities. They are:
- A high-speed, fully automatic vial packaging line with a capacity to pack up to 20 million vials per year with built-in labeling, cartoning, and serialization. The line will be commissioned and validated in Q2 2025.
- Semi-automatic auto-injector packaging line with end-to-end traceability and labeling to be qualified in Q3 2025.
Improving Cold Chain Operations
- To serve increasing demand for temperature-sensitive biologics, cold storage space at the Clinton site was added and completely validated, with 160 pallet positions now available under temperature-controlled 2–8°C conditions. This GMP-area is already up and running and available to enable client supply chains.
- In Europe, Tjoapack’s Etten-Leur site also witnessed a strategic expansion of cold chain capacity. With successful qualification, another 84 pallet positions will be activated in June 2025, making a total of 120 pallet positions at 2–8°C.
Commercialization of Pre-Filled Syringe(PFS) Capabilities
Etten-Leur site has also successfully launched its first commercial project of pre-filled syringe (PFS) packaging. The completely automated PFS line is operational and assisting in the onboarding of further client programs. This advancement is in tandem with the increasing industry trend towards patient-focused drug delivery systems.
Important features of the PFS line are:
- Syringe assembly with or without safety devices
- Automated plunger rod insertion
- Application of safety device
- Attachment of finger flange and back-stop
- Insertion of ancillary parts, i.e., needles
Executive Commentary
“These upgrades directly address the accelerating needs of our clients in the biologics and sterile injectable space,” said Dexter Tjoa, CEO of Tjoapack.
“We are committed to building scalable, compliant infrastructure that ensures the efficient delivery of vital therapies without compromising on flexibility or quality.”
Through the expansion of its injectable packaging capabilities and cold chain offerings, Tjoapack is backing a broad portfolio of primary container formats such as vials, ampoules, syringes, and auto-injectors, all while growing capacity to serve new and existing customers more effectively in North America and Europe.
All infrastructure and lines of packaging are compliant with international GMP standards. The cold storage facilities are ready, validated, and in use, and new lines of packaging will be completely GMP-qualified when commissioned in 2025.
